Anteris Technologies (AVR) Option Scheme Meeting summary
Event summary combining transcript, slides, and related documents.
Option Scheme Meeting summary
12 Jan, 2026Opening remarks and agenda
Meeting convened for Anteris option holders to vote on the proposed Option Scheme of arrangement, as ordered by the Supreme Court of Queensland.
The meeting was held both in person at Hotel Grand Chancellor Brisbane and virtually, with a quorum confirmed.
Only option holders, proxies, corporate representatives, and attorneys could speak, but visitors were welcomed.
Notice of the meeting was distributed via the Scheme Booklet and Supplementary Scheme Booklet released to the ASX.
Board and executive committee updates
Chairman John Seaberg officiated, with directors Wayne Paterson, Stephen Denaro, and Dr. Wen Yi Gu present.
Representatives from Computershare and legal advisors Jones Day attended to assist with the meeting and poll process.
Shareholder proposals
The sole item of business was the Option Scheme resolution, proposing cancellation of Anteris options in exchange for equivalent ATGC options.
The scheme's details, including advantages, disadvantages, and risks, were outlined in the Scheme Booklet and Supplementary Scheme Booklet.
Latest events from Anteris Technologies
- Net loss widened to $76.3M as R&D and IPO costs surged; $80.1M raised in IPO.AVR
H2 202431 Mar 2026 - Net loss widened to $94.2 million in 2025 as R&D spending increased and sales declined.AVR
H2 202531 Mar 2026 - A novel TAVR valve with proven durability and clinical benefits targets major market expansion.AVR
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - DurAVR demonstrates clinical superiority and rapid trial momentum, reshaping the TAVR landscape.AVR
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Shareholders considered and voted on a US redomicile scheme, with results pending ASX release.AVR
Share Scheme Meeting12 Jan 2026 - Two share issue ratifications were voted on with no shareholder questions; results to be released.AVR
EGM 202412 Jan 2026 - Biomimetic TAVR valve targets $10B market with superior hemodynamics and pivotal study launch.AVR
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - OJEMDA's rapid adoption and robust pipeline drive steady growth and future market potential.AVR
TD Cowen 45th Annual Healthcare Conference26 Dec 2025 - US IPO, expanded R&D, and board expertise marked a pivotal year; all proposals recommended.AVR
AGM 202513 Dec 2025